Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2023 | Sequencing bispecific antibodies and CAR-T therapy & the evolving role of bispecifics in myeloma

Hermann Einsele • 26 Jun 2023
EHA 2023
Multiple Myeloma Antibodies CAR-T

Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, comments on evidence supporting the use of CAR-T therapy before bispecific antibodies, discussing how bispecific antibodies will move into earlier lines of treatment and may play a role in consolidation or maintenance following stem cell transplantation (SCT). This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Hermann Einsele

2:44
Moving CAR-T into earlier lines of therapy in multiple myeloma
Hermann Einsele • 17 Feb 2024
0:45
CAR T-cell therapy in lenalidomide-refractory multiple myeloma
Hermann Einsele • 17 Feb 2024
8:16
Results from CARTITUDE-4: cilta-cel for lenalidomide-refractory multiple myeloma
Hermann Einsele • 26 Jun 2023
1:16
Elotuzumab plus KRd versus KRd for newly diagnosed multiple myeloma: Phase III trial results
Hermann Einsele • 26 Jun 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals